For following the competition: what moved in each program, several studies read as one move.
- MHB018A
- MH004
- Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039A
- + 8 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Minghui Pharmaceutical to watchlistEvery Monday by email · turn it off any timePro · free during the beta